Company Profile

Inovio Pharmaceuticals Inc (AKA: Inovio Biomedical Corporation ~ BTX Inc ~ Genetronics Biomedical LTD ~ Biotechno)
Profile last edited on: 4/15/2021      CAGE: 43MD0      UEI: CE2NDNHN33X5

Business Identifier: DNA immunotherapies for HPV, solid tumors and infectious diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

660 West Germantown Pike Suite 110
Plymouth Meeting, PA 19462
   (267) 440-4200
Location: Single
Congr. District: 04
County: Montgomery

Public Profile

With facilities in California but headquartered in Pennsylvania, Inovio Pharmaceuticals Inc, (NASDAQ:INO) -- formerly known as Inovio Biomedical Corporation and before that as Genetronics Inc -- is a biomedical company developing drug and gene delivery systems that use electroporation therapy (EPT) to deliver drugs and genes into cells. Stimulating the body’s immune system remains one of the most promising approaches to addressing the unmet needs of cancers, HIV, hepatitis C virus, and other chronic infectious diseases. The firm has developed a synthetic vaccine technology platform that is progressively showing potential to prevent and treat life-altering diseases. Using their synthetic DNA vaccine technology, Inovio is developing a new generation of potential vaccines against infectious disease. This technology enables the design of synthetic vaccines targeting multiple antigens of a disease with the genetic makeup of the antigen based on different strains, to help provide broader preemptive protection against the mutations that will inevitably occur. Partners and collaborators include Roche, the University of Pennsylvania, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, US Dept. of Homeland Security, and University of Manitoba.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2011 2 Army $834,931
Project Title: Multiagent Synthetic DNA Vaccines Delivered by Noninvasive Electroporation
2004 1 NIH $102,865
Project Title: Ex vivo venous gene delivery by pulsed electric-fields
1999 1 NIH $99,995
Project Title: In Vivo Skin Targeted Gene Therapy By Electroporation
1998 1 NIH $94,301
Project Title: Electrically Enhanced Transdermal Delivery Of Calcitonin
1998 2 NIH $691,052
Project Title: Novel and Efficient Method of Anticancer Drug Delivery

Key People / Management

  J Joseph Kim -- Founder, President; Chief Executive Officer; Director

  Mark Bagarazzi -- Chief Medical Officer

  Prakash Bhuyan -- Vice President, Clinical Development

  Ej Brandreth -- Vice President, Quality Assurance

  Kate Broderick

  Lois Crandell -- former President

  Ildiko Csiki -- Vice President, Clinical Development

  Nagendu B Dev

  Sukhendu B Dev

  Gunter A Hofmann

  Laurent Humeau -- Senior Vice President, Research and Development

  Daniel Jordan -- Vice President, Device Manufacturing Operations

  Robert J Juba Jr -- Vice President, Biological Manufacturing and Clinical Supply Management

  Stephen Kemmerrer -- Vice President of Engineering Operations

  Peter Kies -- Chief Financial Officer

  Jennifer Laux -- Vice President, Commercial

  Jessica C Lee -- Vice President, Clinical Operations and Global Integration

  Niranjan Y Sardesai -- Chief Operations Office

  Ami Shah Brown -- Vice President, Regulatory Affairs

  Jacqueline Shea -- Chief Operating Officer

  Jeffrey Skolnik -- Vice President, Clinical Development

  Scott M White -- Vice President, Clinical Development